MedKoo Cat#: 530028 | Name: Dihydrexidine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dihydrexidine is a dopamine D1 receptor agonist potentially for the treatment of schizotypal personality disorder. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) has been shown to increase prefrontal perfusion in schizophrenia, and is safe and tolerated in patients with schizophrenia.

Chemical Structure

Dihydrexidine
CAS#123039-93-0

Theoretical Analysis

MedKoo Cat#: 530028

Name: Dihydrexidine

CAS#: 123039-93-0

Chemical Formula: C17H17NO2

Exact Mass: 267.1300

Molecular Weight: 267.33

Elemental Analysis: C, 76.38; H, 6.41; N, 5.24; O, 11.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
DAR-0100A; IP-202; DAR0100A; IP202; DAR 0100A; IP 202
IUPAC/Chemical Name
Benzo(a)phenanthridine-10,11-diol, 5,6,6a,7,8,12b-hexahydro-, trans-
InChi Key
BGOQGUHWXBGXJW-RHSMWYFYSA-N
InChi Code
InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m1/s1
SMILES Code
OC1=C(O)C=C2C(CC[C@@]3([H])NCC4=C([C@@]32[H])C=CC=C4)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 267.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res. 2007 Aug;94(1-3):332-41. PubMed PMID: 17596915. 2: Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015 Jan;40(2):446-53. doi: 10.1038/npp.2014.192. PubMed PMID: 25074637; PubMed Central PMCID: PMC4443959. 3: George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007 Jul;93(1-3):42-50. PubMed PMID: 17467956. 4: McCorvy JD, Watts VJ, Nichols DE. Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology (Berl). 2012 Jul;222(1):81-7. doi: 10.1007/s00213-011-2625-5. PubMed PMID: 22222862. 5: Gleason SD, Yin T, Little SP, Delapp N, Witkin JM. Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats. Behav Pharmacol. 2011 Sep;22(5-6):531-9. doi: 10.1097/FBP.0b013e328349aace. PubMed PMID: 21836463. 6: Cueva JP, Gallardo-Godoy A, Juncosa JI, Vidi PA, Lill MA, Watts VJ, Nichols DE. Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. J Med Chem. 2011 Aug 11;54(15):5508-21. doi: 10.1021/jm200334c. PubMed PMID: 21714510; PubMed Central PMCID: PMC3150624. 7: Isacson R, Kull B, Wahlestedt C, Salmi P. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? Neuroscience. 2004;124(1):33-42. PubMed PMID: 14960337. 8: Salmi P, Isacson R, Kull B. Dihydrexidine--the first full dopamine D1 receptor agonist. CNS Drug Rev. 2004 Fall;10(3):230-42. Review. PubMed PMID: 15492773. 9: Lalley PM. D1/D2-dopamine receptor agonist dihydrexidine stimulates inspiratory motor output and depresses medullary expiratory neurons. Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1829-36. doi: 10.1152/ajpregu.00057.2009. PubMed PMID: 19279296; PubMed Central PMCID: PMC2692782. 10: Gleason SD, Witkin JM. Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology (Berl). 2006 May;186(1):25-31. PubMed PMID: 16575553. 11: Wade MR, Nomikos GG. Tolerance to the procholinergic action of the D1 receptor full agonist dihydrexidine. Psychopharmacology (Berl). 2005 Nov;182(3):393-9. PubMed PMID: 16075289. 12: Steele TD, Hodges DB Jr, Levesque TR, Locke KW. D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats. Pharmacol Biochem Behav. 1997 Oct;58(2):477-83. PubMed PMID: 9300608. 13: Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 2002 Jun;301(3):1179-89. PubMed PMID: 12023553. 14: Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol. 1998 Nov-Dec;21(6):339-43. PubMed PMID: 9844789. 15: Salmi P, Ahlenius S. Dihydrexidine produces hypothermia in rats via activation of dopamine D1 receptors. Neurosci Lett. 1997 Oct 24;236(1):57-9. PubMed PMID: 9404951. 16: Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB. Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol. 1993 Sep 28;242(2):165-72. PubMed PMID: 7902811. 17: Johnson BJ, Peacock V, Schneider JS. Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol Biochem Behav. 1995 Aug;51(4):617-22. PubMed PMID: 7675833. 18: Schneider JS, Sun ZQ, Roeltgen DP. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 1994 Nov 7;663(1):140-4. PubMed PMID: 7850462. 19: Steele TD, Hodges DB Jr, Levesque TR, Locke KW, Sandage BW Jr. The D1 agonist dihydrexidine releases acetylcholine and improves cognition in rats. Ann N Y Acad Sci. 1996 Jan 17;777:427-30. PubMed PMID: 8624125. 20: Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, Mailman RB. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J Med Chem. 1994 Jul 22;37(15):2453-60. PubMed PMID: 7914538.